An Observational Study on Drugs Used for Hepatoprotection in Chronic Liver Disease

Chronic liver disease (CLD) is a significant global health concern, with its progression largely influenced by underlying etiological factors.Effective management requires a multifaceted approach that includes pharmacological therapies to manage disease progression with public health interventions focused on prevention and early detection to mitigate the burden of CLD.This study explores the usage trends and therapeutic impact of hepatoprotective drugs in treating CLD, focusing on the therapeutic impact of commonly prescribed hepatoprotective drugs.A 6-month prospective observational study was conducted at a tertiary care hospital, involving 126 patients with CLD, predominantly males (112) aged 36-50 years, with alcoholism being the leading cause.Commonly prescribed drugs included UDCA, SAMe, glutathione, and LOLA.Patients were monitored for changes in serum enzyme levels over two weeks of treatment, and the results indicated a significant reduction in serum transaminases and bilirubin levels, with a greater normalization observed in AST and bilirubin compared to ALT.These findings highlight the therapeutic benefits of appropriate hepatoprotective therapy in improving liver function.The study also emphasizes the importance of combining pharmacological treatment with addressing societal factors and promoting healthier lifestyles to improve liver health outcomes.